相似文献
1
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
Cancer Res. 2020 Oct 1;80(19):4037-4041. doi: 10.1158/0008-5472.CAN-20-1420. Epub 2020 Jun 18.
2
Acquired resistance to cancer immunotherapy.
Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2.
3
The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance.
Cancer Res. 2021 Nov 15;81(22):5596-5604. doi: 10.1158/0008-5472.CAN-21-1466. Epub 2021 Sep 1.
4
Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
Sci China Life Sci. 2021 Apr;64(4):534-547. doi: 10.1007/s11427-019-1735-4. Epub 2020 Aug 17.
5
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Cancer Lett. 2020 Jan 1;468:72-81. doi: 10.1016/j.canlet.2019.10.013. Epub 2019 Oct 9.
6
Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion.
Nat Rev Cancer. 2019 Jul;19(7):405-414. doi: 10.1038/s41568-019-0149-1.
7
Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.
Trends Cancer. 2019 Nov;5(11):704-723. doi: 10.1016/j.trecan.2019.09.009. Epub 2019 Oct 29.
8
Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Trends Cancer. 2017 Aug;3(8):583-592. doi: 10.1016/j.trecan.2017.06.005. Epub 2017 Jul 14.
9
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.
Nat Rev Clin Oncol. 2021 Aug;18(8):527-540. doi: 10.1038/s41571-021-00496-y. Epub 2021 Apr 8.
10
Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Front Immunol. 2018 Apr 25;9:887. doi: 10.3389/fimmu.2018.00887. eCollection 2018.
引用本文的文献
1
Unveiling the heterogeneity and immunotherapy potency of tumor-associated neutrophils in the tumor microenvironment of gastric cancer.
BMC Gastroenterol. 2025 Apr 28;25(1):303. doi: 10.1186/s12876-025-03920-0.
2
DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.
Clin Cancer Res. 2025 May 15;31(10):1988-2009. doi: 10.1158/1078-0432.CCR-24-3029.
3
ITGB1/FERMT1 mechanoactivation enhances CD44 characteristic stemness in oral squamous cell carcinoma via ubiquitin-dependent CK1α degradation.
Oncogene. 2025 Jun;44(20):1530-1544. doi: 10.1038/s41388-025-03317-z. Epub 2025 Mar 5.
4
Exploring thymic stromal lymphopoietin in the breast cancer microenvironment: A preliminary study.
Oncol Lett. 2025 Feb 13;29(4):182. doi: 10.3892/ol.2025.14928. eCollection 2025 Apr.
5
Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review).
Oncol Rep. 2025 Jan;53(1). doi: 10.3892/or.2024.8847. Epub 2024 Nov 29.
6
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.
J Biol Chem. 2024 Dec;300(12):107994. doi: 10.1016/j.jbc.2024.107994. Epub 2024 Nov 14.
7
The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.
Front Immunol. 2024 Oct 16;15:1464421. doi: 10.3389/fimmu.2024.1464421. eCollection 2024.
8
Inferring cell differentiation maps from lineage tracing data.
bioRxiv. 2024 Sep 13:2024.09.09.611835. doi: 10.1101/2024.09.09.611835.
9
Devil in the Dedifferentiated Details: A Rare Case of Primary Pulmonary Dedifferentiated Liposarcoma.
Cureus. 2024 Aug 9;16(8):e66540. doi: 10.7759/cureus.66540. eCollection 2024 Aug.
10
Beta cell dedifferentiation in type 1 diabetes: sacrificing function for survival?
Front Endocrinol (Lausanne). 2024 Jun 6;15:1427723. doi: 10.3389/fendo.2024.1427723. eCollection 2024.
本文引用的文献
1
L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer.
Nat Cancer. 2020 Jan;1(1):28-45. doi: 10.1038/s43018-019-0006-x. Epub 2020 Jan 13.
2
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
Nat Med. 2020 May;26(5):781-791. doi: 10.1038/s41591-020-0818-3. Epub 2020 Apr 13.
3
Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy.
Cancers (Basel). 2020 Apr 1;12(4):852. doi: 10.3390/cancers12040852.
4
Regenerative lineages and immune-mediated pruning in lung cancer metastasis.
Nat Med. 2020 Feb;26(2):259-269. doi: 10.1038/s41591-019-0750-6. Epub 2020 Feb 10.
5
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.
Nat Commun. 2020 Jan 23;11(1):437. doi: 10.1038/s41467-019-14218-7.
6
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype.
Cancer Discov. 2020 Apr;10(4):588-607. doi: 10.1158/2159-8290.CD-19-0435. Epub 2020 Jan 15.
7
Tumor Immunology and Tumor Evolution: Intertwined Histories.
Immunity. 2020 Jan 14;52(1):55-81. doi: 10.1016/j.immuni.2019.12.018.
8
Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma.
Cancer Discov. 2020 Feb;10(2):270-287. doi: 10.1158/2159-8290.CD-19-0780. Epub 2019 Nov 19.
9
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
10
The great escape: tumour cell plasticity in resistance to targeted therapy.
Nat Rev Drug Discov. 2020 Jan;19(1):39-56. doi: 10.1038/s41573-019-0044-1. Epub 2019 Oct 10.
Zotero 插件